Introduction
The prevalence of gastroesophageal reflux disease (GERD) and dyspepsia is now increasing in many Asian countries. 1 Gastroprokinetic agents 2 have an important role to play in conjunction with life-style modifications in the short and longterm medical management of GERD. Mosapride citrate, a novel and potent gastroprokinetic drug, is a selective serotonin 5-HT4 agonist. [3] [4] [5] Chemically, mosapride citrate is a 4-amino-5-
chloro-2-ethoxy-N -[[4-[(4-fluorophenyl)methyl]-2-morpholinyl]-methyl benzamide, and is not yet official in any
Pharmacopeia. So far, no assay procedure has been reported for the determination of this drug either in bulk drug samples or in pharmaceutical formulations. However, its pharmacokinetic studies in rats, 6 dogs, monkeys 7 and in healthy subjects 8 have been reported. The availability of an HPLC method with high sensitivity and selectivity will be very useful for the determination of mosapride citrate in pharmaceutical formulations. The aim of this study was to develop a simple, rapid, precise and accurate reversed-phase HPLC method for the determination of mosapride citrate in bulk drug samples or in pharmaceutical dosage forms.
Experimental

Materials
Mosapride citrate (assigned purity, 99.8%) was a gift sample from M/s. Torrent Pharmaceuticals Ltd. Ahmedabad, India, whereas risperidone (assigned purity, 100.1%) was from M/s. Nepal Pharmaceutical Laboratory Pvt. Ltd. Nepal. Potassium dihydrogen phosphate was of analytical grade, and supplied by M/s. S. D Fine-Chem Limited, Mumbai, India. Methanol and water used were of HPLC grade (Qualigens). Commercially available mosapride citrate tablets claimed to contain 2.5 and 5.0 mg of the drug and were procured from the local market.
Instrumentation
Quantitative HPLC was performed on a gradient highpressure liquid chromatograph (Shimadzu HPLC Class VP series) with two LC-10AT VP pumps, a variable-wavelength programmable UV/VIS detector (SPD-10A VP), an CTO-10AS VP column oven (Shimadzu), an SCL-10A VP system controller (Shimadzu), a disposable guard column [LC-18 (Pelliguard, LC-18, 2 cm, Supelco, Inc., Bellefonte, PA)] and an RP C-18 column (150 mm × 4.6 mm i.d.; particle size 5 µm) was used. The HPLC system was equipped with the software "Class-VP series version 5.03" (Shimadzu).
HPLC conditions
The contents of the mobile phase were methanol and 0.02 M potassium dihydrogen phosphate (pH adjusted to 4.0 with ophosphoric acid) in the ratio of 70:30 v/v. They were filtered before use through a 0.45-µm membrane filter, degassed with a helium spurge for 15 min and pumped from the respective solvent reservoirs to the column at a flow rate of 1.1 mL/min, which yielded a column back pressure of 157 -159 kg/cm 2 . The run time was set at 8.0 min and the column temperature was maintained at 40˚C. The volume of the injection loop was 20 µL. Prior to injection of the drug solutions, the column was equilibrated for at least 30 min with the mobile phase flowing through the systems. The eluents were monitored at 274 nm and data were acquired, stored and analyzed with the software "Class-VP series version 5.03" (Shimadzu).
Recommended procedure
A stock solution of the drug and internal standard was prepared by dissolving 100 mg of mosapride citrate and risperidone separately in a 100-mL volumetric flasks containing 70 mL of methanol (HPLC grade), sonicated for about 15 min and then made up to volume with methanol. Daily working standard solutions of mosapride citrate and risperidone were prepared by suitable dilution of the stock solution with the mobile phase. Ten sets of the drug solution were prepared in the mobile phase containing mosapride citrate at a concentration of 0.1 to 20.0 µg/mL along with a fixed concentration (10 µg/mL) of risperidone as the internal standard. Each of these drug solutions (20 µL) was injected six times into the column, and the peak area and retention time were recorded.
Procedure for pharmaceutical formulations
Twenty tablets were weighed to obtain the average tablet weight, and were then powdered. A sample of the powdered tablets, claimed to contain 50 mg of the active ingredient, was mixed with 25 mL of methanol. This mixture was allowed to stand for 6 h with intermittent sonication to ensure complete solubility of the drug, and was then filtered through a 0.45-µm membrane filter, followed by adding methanol to obtain a stock solution of 1.0 mg/mL. An aliquot of this solution (1.0 mL) was transferred to a volumetric flask and made up to a sufficient volume with the mobile phase to give an expected concentration of 10 µg/mL. All determinations were conducted in triplicate. The same procedure was used to estimate the concentration of the drug in two more commercial brands of mosapride citrate tablets.
Results and Discussion
The development of HPLC methods for the determination of drugs has received considerable attention in recent years because of their importance in the quality control of drugs and drug products. The goal of this study was to develop a rapid HPLC method for the analysis of mosapride citrate in bulk drug samples and its tablet formulations using the most commonly employed RP C-18 column with UV detection.
The retention time (tR) of the mosapride citrate reference substance and the internal standard risperidone (ISD) were 6.10 and 4.07 min, respectively. An HPLC chromatogram shows tR (Fig. 1) . The calibration curve for mosapride citrate was constructed by plotting the ratio of the peak area of mosapride citrate to the peak area of the internal standard (Y) against the concentration (X). It was found to be linear with a correlation coefficient of 0.9999, the representative linear regression equation being Y = -0.00082 + 0.100806X. The method was validated for its intra-and inter-day precision. In the range of 0.1 -20 µg/mL, the coefficients of variation (CV), based on the peak-area ratios for five replicate injections, were found to be between 0.06% and 1.31% (Table 1 ). The inter-day assay precision (3 days, n = 6) was expressed as CV and ranged between 1.25% and 0.54% ( Table 2) .
The regression characteristics, such as standard deviation of the slope (Sb), the standard deviation of the intercept (Sa), standard error of the estimation (Se), %RSD, % range of the error (0.05 and 0.01 level) and detection limit, were calculated for this method (given in Table 3 ).
The HPLC method, developed in the present study, was used to quantify mosapride citrate in tablet dosage forms. Mosapride citrate tablets (2.5 mg and 5.0 mg) were analyzed. The obtained results are given in Table 4 . The average drug content was found to be 101.0% of the labeled amount. No interfering peaks were found in the chromatogram, indicating that the tablet excipients did not interfere with the estimation of the drug by the proposed HPLC method. Also, when a known amount of the drug solution was added to a powdered sample of the tablet dosage form and subjected to an estimation of the drug by the proposed method, there was a high recovery (Table 5) of mosapride citrate (101.40 ± 0.69%), indicating that the proposed procedure for the determination of mosapride citrate in the tablet dosage forms is highly accurate.
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Conclusion
The results of the study showed that the proposed RP-HPLC method is simple, rapid, precise and accurate, which is useful for the routine determination of mosapride citrate in bulk drug samples as well as in its pharmaceutical dosage forms.
